PRESS RELEASES More events are coming soon. Keyword Search Year: 2019201820172016201520142013 01/22/19 Summary ToggleTRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Printer Friendly PDF Version 01/18/19 Summary ToggleI-Mab Biopharma Receives U.S. FDA IND Clearance for Proprietary CD73 Antibody TJD5 Printer Friendly 12/26/18 Summary ToggleTRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer Printer Friendly PDF Version 12/26/18 Summary ToggleTRACON Pharmaceuticals Announces Submission of IND Application for TJ4309 (CD73 Antibody TJD5) for Treatment of Advanced Solid Tumors Printer Friendly PDF Version 12/21/18 Summary ToggleTRACON Pharmaceuticals Announces Top-line Data from Phase 2 TRAXAR Clinical Trial in Renal Cell Carcinoma Printer Friendly PDF Version 12/04/18 Summary ToggleTRACON Pharmaceuticals and I-Mab Biopharma Reschedule Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs Printer Friendly PDF Version 12/03/18 Summary ToggleTRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs Printer Friendly PDF Version 11/29/18 Summary ToggleTRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs Printer Friendly PDF Version 11/19/18 Summary ToggleTRACON Pharmaceuticals Presents Data from Phase 2 Trial of TRC102 and Temodar® in Patients with Recurrent Glioblastoma at Society for Neuro-Oncology Annual Meeting Printer Friendly PDF Version 11/15/18 Summary ToggleTRACON Pharmaceuticals Presents New Circulating Tumor Cell Data from Ongoing Pivotal Phase 3 TAPPAS Trial of TRC105 and Votrient® in Patients with Angiosarcoma Printer Friendly PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
